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ABSTRACT 
 
The UBA domain is a conserved sequence motif among polyubiquitin binding proteins. For the first time, we demonstrate a systematic, 
high throughput approach to identification of UBA domain-interacting proteins from a proteome-wide perspective. Using the rabbit 
reticulocyte lysate in vitro expression cloning system, we have successfully identified eleven proteins that interact with p62’s UBA 
domain, and the majority of the eleven proteins are associated with neurodegenerative disorders, such as Alzheimer’s disease. Therefore, 
p62 may play a novel regulatory role through its UBA domain. Our approach provides an easy route to the characterization of UBA 
domain interacting proteins and its application will unfold the important roles that the UBA domain plays. 
 
 
INTRODUCTION 
 
p62 is a novel cellular protein which was initially identified in 
humans as a phosphotyrosine independent ligand of the src 
homology 2 (SH2) domain of p56
lck (1, 2). p56lck is a member of 
the c-src family of cytoplasmic tyrosine kinases that is found 
predominantly in cells of lymphoid origin (3, 4). In addition to 
the interaction with p56
lck, p62 also associates with the Ser/Thr 
kinase (1, 2), atypical protein kinase C (5, 6), and ubiquitin (7). In 
addition to the SH2 domain, p62 possesses several structural 
motifs, including a ubiquitin associated (UBA) domain that is 
capable of binding ubiquitin nonconvalently (8, 9).  
 
Ubiquitin (Ub) is a small polypeptide of 76 amino acids that can 
be convalently attached to other proteins at specific lysine 
residues through chains composed of one (mono) or several 
ubiquitin moieties (poly). In addition to its classical role in 
protein degradation, ubiquitin is emerging as a signal for protein 
transport and processing (10-12). Conjugation of ubiquitin to 
substrate proteins requires three enzymes: a ubiquitin activating 
enzyme E1, a ubiquitin-conjugating enzyme E2, and a ubiquitin 
ligase E3. Initially, E1 activates ubiquitin by forming a high 
energy thioester intermediate with the C-terminal glycine using 
ATP. The activated ubiquitin is sequentially transferred to E2, 
then to E3 which catalyzes isopeptide bond formation between 
the activated C-terminal glycine of ubiquitin and ε-amino group 
of a lysine residue of the substrate. Following the linkage of the 
first ubiquitin chain, additional molecules of ubiquitin are 
attached to lysine side chains of the previously conjugated moiety 
to form branched polyubiquitin chains. The fate of ubiquitinated 
substrates depends on the number of ubiquitin moieties 
conjugated, as well as, the lysine linkage of Ub-Ub conjugation. 
The conjugation of ubiquitin to eukaryotic intracellular proteins is 
one way in which those proteins are targeted to the proteasome 
for subsequent rapid degradation. This mechanism is particularly 
important for short-lived regulatory proteins such as cyclins, 
cyclin-dependent protein kinase-inhibitors, p53, the nuclear 
factor kappa B precursor, and IκB (13). The ubiquitin-
proteasome system consists of two steps: 1) the target protein is 
conjugated with polyubiquitin molecules, which mark the 
substrate for degradation; 2) the target protein is transferred to 
the 26S proteasome, unfolded and degraded.  
 
The UBA domain is a conserved sequence motif among proteins 
that can bind polyubiquitin. It is comprised of ~45 amino acids 
(13). The amino acids 386-434 of p62, which bind polyubiquitin, Pridgeon et al.    
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has been shown to possess homology to other recently described 
UBA domains (9). Interestingly, proteins with UBA domains are 
more likely to bind polyubiquitin chains over monoubiquitin, 
such as the yeast UBA protein Rad23, a highly conserved protein 
involved in nucleotide excision repair (13). Recently, it has been 
shown that yeast cells lacking two UBA proteins (Dsk2 and 
Rad23) are deficient in protein degradation and that the UBA 
motif is essential for their function in proteolysis (14).  
 
In addition to the important role in recycling of amino acids 
from damaged or misfolded proteins, ubiquitin-protein 
conjugation also has functions unrelated to proteasomal 
targeting. For example, polyubiquitination is required for the 
internalization of several yeast and mammalian cell surface 
proteins into the endocytic pathway (15, 16). Interestingly, p62 
appears to sequester ubiquitinated substrates into a cytoplasmic 
structure referred to as a sequestosome, into which excess 
ubiquitinated proteins are segregated (17). In addition, p62 is an 
immediate early response gene product for a variety of signals 
(18). Thus, p62 appears to play a novel regulatory role for 
polyubiquitinated proteins and may have an essential function in 
cell proliferation and differentiation. We have developed a 
method that will enable identification of protein(s) that interact 
with p62’s UBA domain.  
 
MATERIALS AND METHODS 
 
Materials 
 
Human adult brain library 10×96 well plates with 100 cDNAs per 
well and Gold TNT SP6 Express 96 system plate were purchased 
from Promega Corporation (Madison, WI). [35S] methionine was 
from ICN Biomedicals, Inc. (Irvine, CA). Ubiquitin was from 
Sigma-Aldrich Corporation (St. Louis, MO). Polyubiquitin K48 
chains (Ub2-7 K48) were from Affiniti Research Products Limited 
(Exeter, UK). Autoradiography enhancer En3HANCE was from 
Perkin Elmer, Inc. (Wellesley, MA). JM109 competent cells were 
from Promega Corporation (Madison, WI). Ubiquitin activating 
e n z y m e  E 1  w a s  f r o m  C a l b i o c h e m  ( L a  J o l l a ,  C A ) .  U b i q u i t i n  
conjugating enzyme E2 (UbcH7) was from Affiniti Research 
Products Limited (Exeter, UK). The rabbit polyclonal anti-myc 
antibody, mouse monoclonal anti-myc and anti-ubiquitin 
antibodies were from Santa Cruz Biotechnology, Inc (Santa Cruz, 
CA). Ubiquitin K63 only (Ub K63, ubiquitin with all lysines 
mutated to arginines except K63), Ub K29, Ub K48 were from 
Boston Biochem Inc. (Cambridge, MA). Mammalian Cell 
Transfection Kit was from Specialty Media (Phillipsburg, NJ). 
Agarose-immobilised p62 UBA peptide corresponding to the 
amino acid sequence of the ubiquitin-binding protein p62 residues 
387-436 (PPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNY 
DIGAALDTIQYSKH) was purchased from Affiniti Research 
Products Limited (Exeter, UK).  
 
In vitro expression cloning 
 
To search for novel proteins that bind to the UBA domain of 
p62, we performed in vitro expression cloning (IVEC) using the 
ProteoLink IVEC system. The human adult brain library 96 well 
plates with 100 cDNAs per well was transcribed and translated 
employing the Gold TNT SP6 Express 96 plate and [35S] 
methionine. The TNT Quick-coupled transcription-translation 
system contained a rabbit reticulocyte lysate pre-mixed with most 
of the reaction components necessary to carry out 
transcription/translation in the lysate, including all of the amino 
acids except methionine. [35S] Methionine was used to label newly 
synthesized proteins. The reactions were set up according to the 
manufacturer’s instructions. Rabbit reticulocyte lysate has been 
shown to be capable of carrying out ubiquitination of proteins 
that were translated in such an in vitro translation system (19, 20). 
The reactions mixtures also contained ubiquitin so that the newly 
synthesized proteins could be ubiquitinated. The reactions were 
incubated at 30°C for 2 hours. The resulting proteins were 
assayed to determine their binding ability with p62’s UBA 
domain. Potential positive “hits” were further subdivided and re-
assayed to link individual clones to the protein of interest (Fig. 1).  
 
Fig. 1: Schematic description of the in vitro expression cloning (IVEC) 
system for the primary proteome-wide screen and subsequent isolation of 
cDNAs encoding the proteins of interest (from IVEC manual). 
 
p62 UBA pull down assays 
 
Each translated pool was resuspended in binding buffer (25 mM 
Tris pH 7.5, 125 mM NaCl, 0.1% NP-40) and used as a source of 
protein in p62 UBA pull down assays. Proteins that specifically 
interact with the UBA domain of p62 were isolated by interaction 
with agarose-immobilised p62-UBA peptide (amino acid 387-436 
of p62) (5 µg) for 2 hours at 4ºC, then washed three times in 
washing buffer (25 mM Tris pH 7.6, 100 mM NaCl, 1% NP-40). 
Bound proteins were released by addition of SDS-sample buffer Pridgeon et al.    
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and separated by SDS-PAGE. The SDS-PAGE gels were fixed in 
50% methanol, 10% acetic acid for 30 min, stained in 0.2% 
Commassie Brilliant Blue R-250, 45% methanol, 10% acetic acid 
for 15 min, destained in 10% acetic acid, 50% methanol 
overnight, and enhanced in autoradiography enhancer 
En3HANCE for 1 hr and exposed to X-Ray film.  
 
Library Screening 
 
By combining 4 pools as one mixed pool, 96 protein pools were 
divided into 24 mixed protein pools for use in p62 UBA pull 
down assays. Positive mixed protein pools were selected and 
individual pools were retested for its ability to bind p62’s UBA 
domain. The individual cDNA pool from which the positive 
protein pool was generated was transformed into JM109 
competent cells and plated on LB ampicillin plate. Individual 
colonies were chosen to grow overnight in 1 ml of LB media plus 
ampicillin. Plasmid DNA was purified from the cell culture and 
used for TNT Quick coupled in vitro transcription/ translation. 
The individual protein synthesized from each plasmid DNA 
chosen was screened for its ability to bind p62’s UBA domain. 
To confirm the interaction with p62’s UBA domain, the final 
resulting individual proteins were used in the coupled TNT/p62 
UBA pull down assays. The cDNA inserts were sequenced in the 
Genomics Core Facility at Auburn University and the sequences 
were compared with known sequences in NCBI database by 
BLAST analysis. 
 
Transfection and in vitro ubiquitination 
 
Human embryonic kidney 293 (HEK 293) cells were cultured in 
high glucose Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% heat-inactivated fetal calf serum and transfected 
with myc-tagged HSP70 plasmid using the Mammalian Cell 
Transfection Kit. Cells were harvested and lysed in 1 ml of SDS 
lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM 
NaF, 0.5% TX-100, 1 mM Na3VO4, 2 µg/ml aprotinin, 2 µg/ml 
leupeptin, 1 mM PMSF, 1% SDS) for 30 min on ice, followed by 
centrifugation at 14000 rpm for 15 min at 4°C to remove the 
insoluble fraction. The protein concentration of the supernatant 
was determined using the Bio-Rad DC protein assay reagent with 
bovine serum albumin (BSA) as standard. Equal amount of 
protein (750 µg) was immunoprecipitated with anti-myc and 
collected with agarose-coupled secondary antibody. To the 
agarose beads containing the immunoprecipitated HSP70, 50 µl 
of reaction buffer (50 mM Tris-HCl pH 7.5, 2.5 mM MgCl2, 2 
mM DTT, 2 mM ATP) was added containing 100 ng E1, 200 ng 
E2 (UbcH7), and 100 µg of E3 (Flag-tagged TRAF6) along with 
5 µg GST-WT-Ub, GST-K29R Ub, GST-K48R Ub, GST-K63R 
Ub, or K63 Ub. Control samples without HSP70, E1, E2, E3, or 
GST-WT-Ub were also included. Reactions were carried out by 
continuous shaking at 37°C for 2 hours and then washed three 
times with reaction buffer. The proteins were released by boiling 
for 2 min in SDS-PAGE sample buffer, separated on 7.5% SDS-
PAGE and Western blotted for anti-ubiquitin. 
RESULTS AND DISCUSSION 
 
In vitro transcription/translation 
 
To search for novel proteins that bind to the UBA domain of 
p62, we performed in vitro expression cloning (IVEC) using the 
ProteoLink IVEC system from Promega (Cat. No. L6500). The 
human adult brain library 96 well plates with 100 cDNAs per well 
were transcribed and translated employing the Gold TNT SP6 
Express 96 plate in the presence of [35S] methionine and ubiquitin 
(25 µg/µl, Sigma). By combining 4 protein pools as one mixed 
pool, 96 protein pools were divided into 24 mixed pools (Fig. 2A, 
2B). 
 
Fig. 2: Protein synthesized by the ProteoLink IVEC system in the presence 
of [35S] methionine. 96 protein pools were generated by employing TNT Quick 
Coupled in vitro transcription/translation system. The 96 protein pools were then 
divided into 24 mixed protein pools by combining four protein pools as one 
mixed protein pool. A: 1 day exposure; B: 3 days exposure. 
 
Each lane contained more than 100 proteins (theoretically 400) 
with different molecular weight. Therefore, each lane appeared as 
a smear, indicating that the in vitro transcription/translation 
system from Promega worked successfully. In order to examine 
whether proteins synthesized in the IVEC system are also 
ubiquitinated, Western blot analysis was performed by blotting 
the newly synthesized proteins (in the presence of cold 
methionine instead of 35S methionine) with ubiquitin monoclonal 
antibody. In the mixed protein pools, each of the 24 lanes 
appeared as a smear, indicating that proteins synthesized by the 
IVEC system are also ubiquitinated (Fig. 3A). Furthermore, the 
rabbit reticulocyte lysate in the IVEC system can utilize different 
lysine linkages of ubiquitin (i.e., Ub K29, Ub K48, and Ub K63) Pridgeon et al.    
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for ubiquitination (Fig. 3B). In order to investigate whether the 
agarose-immobilised p62 UBA peptide has binding specificity, a 
mixed protein pool synthesized by IVEC system was tested in a 
pull down assay in the presence of agarose beads alone or in the 
presence of p62 UBA agarose beads (Fig. 3C). Our results 
revealed that proteins that bound to p62’s UBA domain could 
not be pulled down by agarose beads alone, indicating that the 
agarose-immobilised p62 UBA peptide had binding specificity.  
 
 
Fig. 3: Western blot analysis of the proteins synthesized by the ProteoLink IVEC system with ubiquitin antibody and specificity of UBA binding. A: Mixed 
protein pools. 96 protein pools were generated by employing TNT Quick Coupled in vitro transcription/translation system. The 96 protein pools were divided into 24 
mixed protein pools and separated by SDS-PAGE, followed by immunoblotting with ubiquitin monoclonal antibody. B: Proteins synthesized in the IVEC system in the 
absence of ubiquitin (lane 1) or presence of wild type ubiquitin (lane 2), ubiquitin K29 (lane 3), ubiquitin K48 (lane 4), and ubiquitin K63 (lane 5). C: Proteins synthesized 
in the IVEC system were labeled by 35S methionine and used for pull down assays. Lane 1: proteins recovered with agarose beads alone; Lane 2: proteins recovered with 
p62 UBA agarose beads. 
 
p62 UBA pull down and library screen 
 
In order to identify proteins that bind to p62’s UBA domain, p62 
UBA pull down assays were performed. Out of the 24 mixed 
protein pools, several pools contained [35S] methionine-labeled 
bands in the primary p62 UBA pull down assays (Fig. 4). We 
chose 6 pools (pool # 2, 4, 8, 14, 20, 21) because of their 
stronger signal to specifically identify which individual protein 
pool in the mixed pools has the ability to bind to p62’s UBA 
domain. Therefore, a secondary screen was conducted on the 6 
positive individual mixed pools (representing 24 individual 
protein pools) which bound with p62’s UBA domain (Fig. 5). 
Mixed protein pool # 2 generated a positive protein with 
molecular weight of 51 KDa (Fig. 4), and only individual protein 
pool “c” out of the four protein pools (a, b, c, d) that comprised 
protein pool #2 had a protein with the same molecular weight 
(Fig. 5). Depending on the size of the protein pulled down in the 
secondary screen compared to the primary screen (Fig. 4), 
individual protein pools “c”, “h”, “i”, “o”, “t”, and “v” were 
identified (Fig. 5). 
 
 
Fig. 4: Pull down assay of p62’s UBA domain with proteins (mixed protein 
pool) synthesized by IVEC system in the presence of [35S] methionine. The 
24 mixed proteins pools were incubated with agarose-immobilised p62 UBA 
beads for 2 hours at 4ºC and washed three times in washing buffer. Bound 
proteins were released by boiling for 2 min in SDS-PAGE sample buffer and 
separated on 10% SDS-PAGE. Positive “hits” were marked by arrows and the 
positive protein pools were selected for subsequent deconvulation. 
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Fig. 5: Pull down assay of p62’s UBA domain with proteins (individual 
protein pool) synthesized by IVEC system in the presence of [35S] 
methionine. The 6 positive mix protein pools (# 2, 4, 8, 14, 20, 21 from Fig. 4) 
representing 24 individual protein pools were incubated with agarose-immobilised 
p62 UBA beads for 2 hours at 4ºC and the beads were washed three times in 
washing buffer. Bound proteins were released by boiling for 2 min in SDS-PAGE 
sample buffer and separated on 10% SDS-PAGE. Positive “hits” were marked by 
arrows and the positive individual protein pools were underlined. 
 
To specifically identify which protein in the individual protein 
pool has the ability to bind p62’s UBA domain, the cDNAs from 
the positive individual protein pools were then transformed into 
JM109 competent cells and plated out on LB ampicillin plates. 
Individual colonies were chosen to grow overnight in 1 ml of LB 
media plus ampicillin. Plasmid DNAs were purified from the cell 
culture and used for TNT Quick coupled in vitro 
transcription/translation. The individual protein synthesized 
from each plasmid DNA was retested for its ability to bind p62’s 
UBA domain. By synthesizing individual protein from individual 
plasmid using the Gold TNT Quick coupled in vitro 
transcription/translation system and subjecting them to p62 
UBA pull-down assays, 11 positive clones were isolated from the 
6 positive individual pools. It is not surprising that 5 more clones 
showed binding ability with p62’s UBA domain since there are 
100 cDNAs in each positive individual pool and some of them 
could have lower binding ability and therefore showed weak 
signal in the mixed protein pool. It is also possible that they are 
not as efficiently synthesized in the mixed TNT reaction as in the 
individual TNT reaction in which only one cDNA was used as 
template. The 11 positive plasmids were sequenced and 
compared with known cDNA sequences in NCBI database using 
BLAST analysis with results shown in Table 1.  
 
Interestingly, the proteins identified in the screen fall into three 
distinct categories. One set are proteins that are associated with 
Alzheimer’s disease, including myelin basic protein, 14-3-3 
protein, syntaxin binding protein munc18, transketolase, heat 
shock protein HSP70, reelin, and calcium/calmodulin kinase II 
(Table 1). Significant decrease in the amount of myelin basic 
protein has been reported in the white matter of Alzheimer’s 
disease patients, accompanied by increased quantities of β-
amyloid peptides (21). The presence of β-amyloid peptides 
containing senile plaques and neurofibrillary tangles are the two 
major pathological features in the brain of patients with 
Alzheimer’s disease (22). Interestingly, 14-3-3 proteins have also 
been demonstrated to be components of neurofibrillary tangles 
of Alzheimer’s disease brains (23). Syntaxin binding protein 
munc18 can powerfully regulate amyloid precursor protein 
metabolism and β-amyloid secretion through direct and indirect 
interactions with X11 proteins (24). The activity of transketolase 
has been reported to be reduced in dementia of Alzheimer’s type 
brain (25). Heat shock protein HSP70 expression is significantly 
increased in the temporal cortex of patients with Alzheimer’s 
disease (26). Besides HSP70, other heat shock proteins are also 
linked with Alzheimer’s disease. For example, increased synthesis 
of HSP27 has been suggested to play a role in preventing 
neuronal injury in AD (27), and alpha-crystallin heat shock 
protein has a close relationship with neurofibrillary tangles of AD 
brains (28). Reelin is a large secreted protein that controls cortical 
layering by signaling through the very low density lipoprotein 
receptor and apolipoprotein E receptor 2, thereby inducing 
tyrosine phosphorylation of the adaptor protein Disabled-1 
(Dab1) and suppressing tau phosphorylation (29). Neurofibrillary 
tangles comprised of highly phosphorylated tau proteins are a key 
component of Alzheimer’s disease (30). Enhanced activity of 
calcium/calmodulin kinase II has been suggested to contribute to 
phosphorylation of tau protein and lead to neurofibrillary tangle 
deposition and neuronal death in Alzheimer’s disease (31). 
Although the relationship between p62 and neurofibrillary tangles 
or neuritic plaques is unclear, both neurofibrillary tangles and 
dystrophic neuritis of neuritic plaques are associated with 
ubiquitin (32), suggesting that dysfunction in ubiquitin-mediated 
proteolysis and the resulting accumulation of ubiquitin-
conjugated proteins may contribute to the origination of 
dystrophic neuritis and neurofibrillary tangles. Furthermore, p62 
has been recently reported to accumulate early in neurofibrillary 
tangles in Alzheimer’s disease (33), suggesting that p62 may play 
an important role in Alzheimer’s disease by interacting with those 
proteins through its UBA domain. 
 
A second set of proteins identified in the screen that bind to 
p62’s UBA domain are associated with brain development, 
including homeobox protein Meis2 and unc51 like kinase II 
(Table 1). Although Meis proteins are not extensively studied in 
humans, these proteins have been shown to be required for 
hindbrain development in the zebrafish (34). Unc51 like kinase II 
has been demonstrated to play a role in axonal elongation (35, 
36), which is needed for the formation of complicated neuronal 
networks. The third set of proteins that exhibit ability to bind 
p62’s UBA domain are proteins that are linked with other 
neurodegenerative diseases, including FK506 binding proteins 
and nuclear receptor corepressor I (Table 1). FK506 (tacrolimus) 
is a potent immunosuppressive drug used in the treatment of 
patients after organ transplantation and in selected autoimmune 
disorders (37). FK506 is activated upon binding to members of 
the immunophilin family of proteins, which were designated as 
FK506 binding proteins (38). Immunophilins are chaperone 
proteins and FK506 binding proteins have been suggested as 
therapeutics for neurological disorders (39, 40). Nuclear receptor 
corepressor I has been suggested to play a role in Huntington’s 
disease because it is able to interact with huntingtin (41). The 
proteins identified here suggest that p62’s UBA domain has the 
ability to interact with multiple proteins that play important roles 
in neurodegenerative diseases. Further screening from the whole 
genome-wide perspective will be necessary to define the 
important role that p62’s UBA domain plays. Pridgeon et al.    
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Table 1: Sequencing result of individual cDNA/Protein that binds to p62’s UBA domain 
Well #  Plasmid        cDNA Homology and resulting protein  Putative function 
A7  # 19  98%  Myelin basic protein  Decreased in Alzheimer’s Disease (AD) 
A7  # 23  98%  14-3-3 protein zeta isoform  Located in neurofibrillary tangles of AD 
B4  # 18  96%  Syntaxin binding protein (munc18) 1  Interact with X11 and reduce β-amyloid 
B4  # 24  99%  FK506 binding protein (FKBP) 14  Ligands as neurological disorders therapeutics 
C5  # 19  99%  Homeobox protein Meis2  Brain development 
E7  # 9  97%  Transketolase  Decreased activity in dementia of AD 
E7  # 15  100%  Heat shock cognate hsp70  Protect cell death 
F3  # 10  97%  Reelin isoform b  Suppress tau Phosphorylation 
G8  # 16  94%  Calcium/calmodulin kinase II  May phosphate tau, leading to AD 
G8  # 24  99%  Unc51 like kinase II  Plays role in axonal elongation 
G10  # 13  98%  Nuclear receptor co-repressor 1   Link with Huntington’s disease 
 
In vitro ubiquitination 
 
It has been reported that polyubiquitin chains assembled through 
lysine 48 of ubiquitin act as a signal for substrate proteolysis by 
the 26S proteasome (42-44). In order to understand whether the 
proteins identified in our screen bind to the p62’s UBA domain 
through lysine 48 (K48), polyubiquitin K48 chains were added to 
the p62 UBA pull down assay (Fig. 6). Inclusion of polyubiquitin 
K48 chains in the assay should compete for the binding of 
substrate to the p62’s UBA domain and reduce the interaction of 
those proteins with the p62’s UBA domain if those proteins are 
assembled through K48 chains. An alternative interpretation for 
polyubiquitin K48 chain competition is that the ubiquitin chains 
are competing for the same binding site as the binding partners 
which are either ubiquitinated or non-ubiquitinated. We 
randomly chose five proteins out of the 11 binding partners for 
the competition pull down (Fig. 6). Out of the five proteins, four 
proteins (# 2, 3, 4, and 5) showed reduced binding ability with 
p62’s UBA domain when polyubiquitin K48 chains were 
included (Fig. 6A, 6B). However, K48 chains failed to compete 
with HSP70, suggesting that p62’s UBA domain binds to HSP70 
through a ubiquitin lysine linkage other than K48. Interestingly, it 
has been reported that heat shock protein 70 cognate (HSP70) is 
ubiquitinated by CHIP (carboxyl terminus of Hsc70-interacting 
protein) via ubiquitin chain synthesis that uses either K29 or K63 
(45). In order to examine which lysine linkage utilized by HSP70 
binds to p62’s UBA domain, in vitro ubiquitination assay was 
performed by incubating lysates from HEK cells expressing 
HSP70 with E1, E2, and E3 in reaction buffer (50 mM Tris-HCl 
pH 7.5, 2.5 mM MgCl2, 2 mM DTT, 2 mM ATP). As control, the 
ubiquitination of HSP70 utilizing the rabbit reticulocyte lysate 
was also investigated by Western blot analysis. Our results 
revealed that HSP70 was ubiquitinated in the IVEC system (Fig. 
7A, 7B), and the rabbit reticulocyte lysate contained enzymes 
such as TRAF6 (E3) and UbcH7 (E2) for in vitro ubiquitination 
(Fig. 7C). 
 
 
Fig. 6: Polyubiquitin K48 chain (Ub2-7 K48) competition pull down assay.  
A: The individual proteins were synthesized by employing TNT Quick Coupled in 
vitro transcription/translation system and incubated with 5 µg agarose-
immobilised p62 UBA beads +/- polyubiquitin K48 chains for 2 hours at 4ºC. 
The beads were washed three times in washing buffer and bound proteins were 
released by boiling for 2 min in SDS-PAGE sample buffer and separated on 10% 
SDS-PAGE.  B: The autoradiogram was scanned and the relative amount of 
protein (%) bound to p62’s UBA domain +/− polyubiquitin K48 chains was 
graphed. The amount of protein bound to p62’s UBA domain without addition 
of polyubiquitin K48 chains was considered 100%. 1: HSP70; 2: Meis2; 3: 14-3-3; 
4: Reelin; 5: MBP. 
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TRAF6 was chosen as an E3 in this in vitro ubiquitination assay 
due to its RING domain, a common feature of E3 ligases, and 
the observation that p62 is a scaffold for TRAF6 interaction (46). 
Therefore,  in vitro ubiquitination assays using the E1-E2-E3 
system were performed in the presence of either ubiquitin wild 
type or ubiquitin mutants (K29R, K48R, and K63R). If one lysine 
mutant blocks the ubiquitination of HSP70, it would suggest that 
the ubiquitination of HSP70 utilizes that specific lysine linkage. 
Our results revealed that HSP70 utilizes K63 linkage to assemble 
polyubiquitin chains to bind to p62’s UBA domain since only the 
K63R ubiquitin mutant blocked the ubiquitination of HSP70 
(Fig. 8A). A similar result was also observed when reactions were 
conducted with wild type ubiquitin or mutant ubiquitin with all 
lysines mutated to arginines except K63 and the ubiquitination of 
HSP70 occurred only in the reaction that has either intact K63 
ubiquitin or wild type ubiquitin (Fig. 8B). This finding is 
consistent with previous reports (45), demonstrating that HSP70 
is K63-polyubiquitinated. Furthermore, the in vivo interaction of 
HSP70 and p62 was confirmed by transfecting myc-tagged 
HSP70 into HEK 293 cells in the presence of the proteasome 
inhibitor MG132 and subjecting cell lysates to p62 
immunoprecipitation and Western blot with anti-myc antibody 
(Fig. 8C). The interaction between HSP70 and p62 in vivo took 
place only when MG132 was included, suggesting that the 
interaction  in vivo is dependent upon the ubiquitination of 
HSP70. The specific type of polyubiquitin chain recognized by 
p62’s UBA domain is not yet known and studies are underway 
lab to determine p62’s interaction with specific polyubiquitin 
chains, however, our preliminary studies suggest that p62’s UBA 
domain may recognize K63 linked polyubiquitin chains.  
 
Fig. 7: In vitro ubiquitination using the rabbit reticulocyte lysate. A: HSP70 
Protein was synthesized employing TNT Quick Coupled in vitro 
transcription/translation system in the presence of ubiquitin, resolved on 10% 
SDS-PAGE gels, transferred to nitrocellulose membrane and western blotted 
with ubiquitin monoclonal antibody. B: HSP70 Protein was synthesized 
employing TNT Quick Coupled in vitro transcription/translation system in the 
presence of ubiquitin and 35S-methionine, resolved on 10% SDS-PAGE and 
exposed to X-ray film. C: Western blot of rabbit reticulocyte lysate with TRAF6 
(E3) and UbcH7 (E2). 
 
Fig. 8: In vitro ubiquitination of HSP70 using E1-E2-E3 system and in vivo 
interaction of p62 with HSP70. A:  myc-tagged HSP70 protein expressed in 
HEK cells was immunoprecipitated by myc-polyclonal antibody and used as a 
source of substrate for in vitro ubiquitination +/− E1, E2, E3, WT-Ub, Ub K29R, 
Ub K48R, Ub K63R. The reactions were separated on 10% SDS-PAGE and 
Western blotted with myc monoclonal antibody (bottom panel) to detect HSP70 
or with ubiquitin monoclonal antibody (top panel) to detect ubiquitination.  B: 
myc-tagged HSP70 protein expressed in HEK cells was immunoprecipitated by 
myc-polyclonal antibody and used as a source of substrate for in vitro 
ubiquitination in the absence or presence of wild type ubiquitin or Ub K63R or 
Ub K63. The reactions were separated on 10% SDS-PAGE and Western blotted 
with myc monoclonal antibody (bottom panel) to detect HSP70 or with ubiquitin 
monoclonal antibody (top panel) to detect ubiquitination. C: In vivo interaction of 
HSP70 and p62. Transfection of myc-tagged HSP70 into HEK293 cells was 
performed and the cell lysates were subjected to immunoprecipitation with p62 
polyclonal antibody, followed by Western blot with anti-myc monoclonal 
antibody. 
 
In summary, for the first time, we demonstrate a systematic 
approach to identify UBA domain binding proteins from a 
proteome wide perspective. This approach could be readily 
adapted to high throughput screening. Using the rabbit 
reticulocyte lysate in vitro expression cloning system, we have 
successfully identified eleven proteins in the human adult brain 
that interact with the UBA domain of p62, and the majority of 
the eleven proteins are associated with neurodegenerative 
disorders, such as Alzheimer’s disease. This is a very interesting 
finding since 9600 cDNAs have been screened and only 11 of 
them showed binding specificity with p62’s UBA domain. Studies 
are underway to unfold the functional roles of p62 in the 
ubiquitin system. Our approach provides an easy route to the 
characterization of UBA domain binding proteins at the level of 
the whole proteome, its application will unfold the important 
roles that p62’s UBA domain plays. This method could be easily 
adapted to identify proteins that interact with other UBA 
domains as well.  
 Pridgeon et al.    
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PROTOCOLS 
 
In vitro transcription/translation 
 
1.  Remove one Gold TNT SP6 Express 96 plate from storage at −80°C and thaw on ice for 10 minutes. Briefly spin to pull material 
down to the bottom of the wells. 
2.  Remove one ProteoLink Human Adult Brain cDNA library plate from storage at −20°C and thaw. Briefly spin to pull material 
down to the bottom of the wells. 
3.  Carefully peel away and discard the seal. The seal of the library should be discarded to avoid cross contamination. 
4.  For each reaction, i.e., one 20 µl pre-dispended well of lysate, add 1 µl of [35S] methionine (1000Ci/mol at 10 mCi/ml), 2 µl of 
cDNA template (0.25 µg/µl), 1 µl of ubiquitin (25 µg/µl), 1 µl of nuclease-free water. Seal the plate containing the reactions with a 
new adhesive plate seal. Reseal the cDNA library plate with a new adhesive plate seal and store it at −20°C. 
5.  Gently vortex the plate to mix. 
6.  Incubate the reaction at 30°C for 2 hours. 
7.  Use the translated proteins as source for p62 UBA pull down assays. 
 
p62 UBA pull down assay 
 
1.  Wash p62 UBA agarose beads (Affiniti, UK) with binding buffer (25 mM Tris pH 7.5, 125 mM NaCl, 0.1% NP-40) three times. 
2.  Add equal volume to p62 UBA beads to make 50% slurry. 
3.  Add 5 µl of 50% p62 UBA beads to each TNT protein pool (mixed pools or individual pool). 
4.  Bring all reactions to a total of 50 µl with binding buffer. 
5.  Gently shake the reactions in a mixer at 4°C for 2 hours. 
6.  Wash the beads with 500 µl of washing buffer (25 mM Tris pH 7.6, 100 mM NaCl, 1% NP-40) three times to remove the unbound 
proteins. 
7.  Add 50 µl of SDS sample buffer, boiling for 2 minutes to release the bound proteins. Separate proteins on 10% SDS-PAGE. 
 
Transfection and in vitro ubiquitination 
 
1.  Culture HEK 293 cells in high glucose Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat-inactivated fetal calf 
serum. 
2.  Transfect HEK 293 cells with 10 µg of myc-tagged HSP70 plasmid by calcium phosphate procedure. 
3.  After 48 hours transfection, lyse cells in 1 ml of triton lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM NaF, 0.5% TX-
100, 1 mM Na3VO4, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 1 mM PMSF) containing 1% SDS for 30 min on ice. 
4.  Centrifuge at 14000 rpm for 15 min at 4°C to remove the insoluble fraction.  
5.  Measure the protein concentration using the Bio-Rad DC protein assay reagent with bovine serum albumin as standard.  
6.  Combine equal amount of protein (750 µg) with 4 µg of anti-myc monoclonal antibody in SDS lysis buffer. The total volume of 
the reaction is 1 ml. 
7.  Rotate reactions gently at 4°C for 2 hours. 
8.  Add 50 µl of 50% anti-mouse IgG agarose beads in triton lysis buffer to each reaction. Rotate reactions gently at 4°C for 2 hours. 
9.  Wash agarose beads three times with triton lysis buffer to remove unbound protein. 
10.  Wash agarose beads once with reaction buffer (50 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2, 2 mM DTT, 2 mM ATP).  
11.  To the agarose beads containing the immunoprecipitated HSP70, add 100 ng E1(Calbiochem), 200 ng E2 (UbcH7, Affiniti, UK), 
100 µg of E3 (Flag-tagged TRAF6), 5 µg GST-WT-Ub, GST-K29R Ub, GST K48R Ub, or GST-K63R Ub in 50 µl of reaction 
buffer. Also include control samples without HSP70, E1, E2, E3, or GST-WT-Ub.  
12.  Shake the reactions continuously at 37°C for 2 hours. 
13.  Wash beads three times with reaction buffer.  
14.  Add 50 µl of SDS sample buffer, boiling for 2 minutes to release the bound proteins. Separate proteins on 10% SDS-PAGE. 
 